Moderna prepares to launch four vaccines

The pharmaceutical company Moderna is in the last phase of clinical testing for the launch of four vaccines against latent infections caused by viruses of the herpesvirus family.

The pharmaceutical company Moderna announced that it began the last phase of clinical trials for the development of four new vaccines against latent infections, including chickenpox and herpes, as well as the norovirus responsible for gastroenteritis outbreaks.

The four vaccines against latent infections are for diseases caused by viruses of the herpesvirus family: cytomegalovirus (the infection that causes the most birth defects in the United States), Epstein-Barr virus (the main cause of acute infectious mononucleosis), herpes virus simplex and the varicella-zoster virus (responsible for chickenpox).

In addition, the pharmaceutical company is in the last phase of development of a vaccine against norovirus, which causes outbreaks of gastroenteritis around the world and about 200,000 deaths a year.

Moderna also took the opportunity to announce a new generation vaccine against Covid-19 effective for both the omicron BA.4 and BA.5 variants and the original strains of SARS-CoV-2.

The new generation of vaccine against Covid-19 has allowed the company to develop a vaccine candidate against flu and Covid-19 for people over 50 years of age.

The company valued the global endemic Covid-19 market at $10 billion annually.

With information from Doble Llave

(Reference image source: Mufid Majnun in Unsplash)

Visit our news channel on Google News and follow us to get accurate, interesting information and stay up to date with everything. You can also see our daily content on Twitter and Instagram

You might also like